Grand Theravac Life Sciences (Nanjing) Co., Ltd.

Quick facts

Phase 3 pipeline

• TVAV-008 · Immunology
  TVAV-008 is a small molecule that targets the S1P1 receptor.

Phase 2 pipeline

• TVAX-008

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Grand Theravac Life Sciences (Nanjing) Co., Ltd. portfolio CI brief
• Grand Theravac Life Sciences (Nanjing) Co., Ltd. pipeline updates RSS